NASDAQ:EPZM - Epizyme Stock Price, Forecast & News

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme Inc (NASDAQ:EPZM) released its earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.11. The biopharmaceutical company had revenue of $5.72 million for the quarter, compared to analysts' expectations of $5.50 million. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. View Epizyme's Earnings History.

Epizyme is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Epizyme.

9 brokerages have issued 12 month target prices for Epizyme's stock. Their forecasts range from $18.00 to $36.00. On average, they expect Epizyme's stock price to reach $27.14 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View Analyst Price Targets for Epizyme.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

News stories about EPZM stock have trended neutral this week, according to InfoTrie. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Epizyme earned a news impact score of 0.4 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Epizyme.

Epizyme saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 8,780,000 shares, an increase of 9.5% from the December 31st total of 8,020,000 shares. Based on an average daily trading volume, of 919,900 shares, the days-to-cover ratio is currently 9.5 days. Approximately 11.5% of the company's stock are sold short. View Epizyme's Current Options Chain.

Some companies that are related to Epizyme include Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Global Blood Therapeutics (GBT) and BridgeBio Pharma (BBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Amarin (AMRN), Clovis Oncology (CLVS), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Novavax (NVAX), TG Therapeutics (TGTX) and Verastem (VSTM).

Epizyme's stock is owned by a number of of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (6.75%), Victory Capital Management Inc. (2.91%), Victory Capital Management Inc. (2.73%), State Street Corp (2.71%), FMR LLC (2.45%) and Loomis Sayles & Co. L P (1.76%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Institutional Ownership Trends for Epizyme.

EPZM stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, FMR LLC, State Street Corp, Palo Alto Investors LP, UBS Group AG, Rafferty Asset Management LLC, Goldman Sachs Group Inc. and Citigroup Inc.. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Insider Buying and Selling for Epizyme.

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., Victory Capital Management Inc., State of New Jersey Common Pension Fund D, Candriam Luxembourg S.C.A., Delta Investment Management LLC, EAM Investors LLC and Geode Capital Management LLC. View Insider Buying and Selling for Epizyme.

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EPZM stock can currently be purchased for approximately $21.64.

Epizyme has a market capitalization of $1.97 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

The official website for Epizyme is http://www.epizyme.com/.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]